Month: April 2019

Positive Pilot Phase 3 Data Position VistaGen’s PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder

PH94B has potential to be the First FDA-Approved PRN Treatment for Social Anxiety Disorder New Findings Presented at the 2019...

error: Content is protected !!